Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer  

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Clinical Updates in Treating Advanced Prostate Cancer

ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

What are your thoughts about this new combination of enzalutamide and radium-223 as a first-line therapy in metastatic castration-resistant prostate cancer?


Is PEACE III a game changer? Does it change the guidelines?

Videos

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

Treatment Landscape and Sequencing of Therapies

Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.

Treatment Timelines Related to Disease State and Use of Monotherapy

Panelists discuss how genetic testing for germline mutations is becoming increasingly crucial in the management of prostate cancer, enabling personalized treatment approaches and informing patient care decisions.

Genetic Testing – Germline

Panelists discuss how recent data on androgen receptor pathway inhibitor–based combination regimens highlight their potential to enhance treatment outcomes for advanced prostate cancer, underscoring the importance of integrating these findings into clinical practice.

Recent Data on ARPI-Based Combination Regimens

Panelists discuss how somatic genetic testing is essential for identifying actionable mutations in prostate cancer, guiding targeted therapies, and improving treatment outcomes for patients.

Genetic Testing – Somatic

Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.

Use of Bone Protection Agents

Panelists discuss how the ARANOTE trial exploring darolutamide in combination with androgen deprivation therapy shows potential benefits in managing advanced prostate cancer.

ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)

Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.

ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

Panelists discuss how the SPLASH trial investigating 177Lu-PNT2002 demonstrates promising efficacy in treating advanced cancer through targeted radionuclide therapy.

ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)

Panelists discuss how recent advancements in targeted therapies and a multidisciplinary approach can significantly enhance the management and care of patients with metastatic prostate cancer.

ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

EP: 1.Treatment Landscape and Sequencing of Therapies

EP: 2.Treatment Timelines Related to Disease State and Use of Monotherapy

EP: 3.Genetic Testing – Germline

EP: 4.Recent Data on ARPI-Based Combination Regimens

EP: 5.Genetic Testing – Somatic

EP: 6.ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

EP: 7.Use of Bone Protection Agents

EP: 8.ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)

EP: 9.ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

EP: 10.ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)

EP: 11.Key Takeaways and Looking Ahead

Latest Conference Coverage